| * Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor R |
| * Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With C |
| * Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Ca |
| * Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel |
| * Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer |
| * Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease |
| * First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study |
| * Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease |
| * Neuroendocrine Neoplasms of the Lung: A Prognostic Spectrum |
| * Patterns of Care in Early-Stage Breast Cancer Survivors in the First Year After Cessation of Active Treatment |
| * Factors Related to Underuse of Surveillance Mammography Among Breast Cancer Survivors |
| * Psychological Distress in Men With Breast Cancer |
| * Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Famil |
| * Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases |
| * Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primar |
| * Low Value of [18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Primary Staging of Early-Stage Cervical Cancer Before |
| * Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Br |
| * Unconventional Anticancer Agents: A Systematic Review of Clinical Trials |
| * Impact of the Year 2000 Medicare Policy Change on Older Patient Enrollment to Cancer Clinical Trials |
| * Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leu |
| * Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Child |
| * Decision Making in Pediatric Oncology: Who Should Take the Lead The Decisional Priority in Pediatric Oncology Model |
| * Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic A |
| * Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma |
| * Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma |
| * Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American S |
| * Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment E |
| * Vascular Endothelial Growth Factor-D and Its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma |
| * Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status o |
| * New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis |
| * Gene Expression Profiling of Localized Esophageal Carcinomas: Association With Pathologic Response to Preoperative Chemoradiation |
| * EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the |
| * Tumor Necrosis Factor-–Induced Protein 3 As a Putative Regulator of Nuclear Factor-B–Mediated Resistance to O6-Alkylating Agents i |
| * High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression of PTEN in Uveal Melanoma |
| * Array-Based Comparative Genomic Hybridization Analysis Reveals Recurrent Chromosomal Alterations and Prognostic Parameters in Prim |
| * Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non–Small-Cell Lung Cancer Tumor |
| * Prognostic Significance of Chromosome Aberrations in High-Grade Soft Tissue Sarcomas |
| * Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of |
| * Correlates of Return to Work for Breast Cancer Survivors |
| * Assessing BRCA Carrier Probabilities in Extended Families |
| * The Use of Radiation As a Component of Breast Conservation Therapy in National Comprehensive Cancer Network Centers |
| * Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Stud |
| * Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas |
| * Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, R |
| * OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCO |
| * Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors |
| * Similar Outcomes Between African American and Non–African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report |
| * The Effect of Race on Invasive Staging and Surgery in Non–Small-Cell Lung Cancer |
| * Astragalus-Based Chinese Herbs and Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Meta-Analysis of Randomize |
| * Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: |
| * Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chron |
| * Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplant |
| * High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positiv |
| * Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic |
| * Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer |
| * Risk of Selected Subsequent Carcinomas in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study |
| * Thromboembolism in Hospitalized Neutropenic Cancer Patients |